356 related articles for article (PubMed ID: 11551579)
1. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
[TBL] [Abstract][Full Text] [Related]
2. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
Benhamou Y; Thibault V; Vig P; Calvez V; Marcelin AG; Fievet MH; Currie G; Chang CG; Biao L; Xiong S; Brosgart C; Poynard T
J Hepatol; 2006 Jan; 44(1):62-7. PubMed ID: 16274835
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.
Gilson RJ; Chopra KB; Newell AM; Murray-Lyon IM; Nelson MR; Rice SJ; Tedder RS; Toole J; Jaffe HS; Weller IV
J Viral Hepat; 1999 Sep; 6(5):387-95. PubMed ID: 10607255
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil: a review of its use in chronic hepatitis B.
Dando T; Plosker G
Drugs; 2003; 63(20):2215-34. PubMed ID: 14498759
[TBL] [Abstract][Full Text] [Related]
6. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
[TBL] [Abstract][Full Text] [Related]
11. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
Herreros de Tejada Echanojáuregui A; Moreno Planas JM; Rubio González E; Portero Azorin F; López Monclús J; Revilla Negro J; Lucena de la Poza JL; Sánchez Turrión V; Barrios Peinado C; Cuervas-Mons Martínez V
Transplant Proc; 2005 Apr; 37(3):1507-8. PubMed ID: 15866657
[TBL] [Abstract][Full Text] [Related]
12. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
13. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
[TBL] [Abstract][Full Text] [Related]
15. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
[TBL] [Abstract][Full Text] [Related]
16. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
17. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
Schiff ER; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann HL; Samuel D; Zeuzem S; Lilly L; Rendina M; Villeneuve JP; Lama N; James C; Wulfsohn MS; Namini H; Westland C; Xiong S; Choy GS; Van Doren S; Fry J; Brosgart CL;
Hepatology; 2003 Dec; 38(6):1419-27. PubMed ID: 14647053
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
[TBL] [Abstract][Full Text] [Related]
20. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
